Metreleptin for treating lipodystrophy (HST14)
Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults
Search results
19 results
-
-
COVID-19 rapid guideline: delivery of radiotherapy (NG162)
The purpose of this guideline is to maximise the safety of patients who need radiotherapy and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for radiotherapy to patient needs if services become limited because of the COVID-19 pandemic.
-
COVID-19 rapid guideline: critical care in adults (NG159)
The purpose of this guideline is to maximise the safety of patients who need critical care during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.
-
COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)
The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.
-
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)
The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.
-
Leukomed Sorbact for preventing surgical site infection (MTG55)
Evidence-based recommendations on Leukomed Sorbact for preventing surgical site infection after caesarean section or vascular surgery
-
The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal (MTG54)
Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal
-
The PLASMA system for transurethral resection and haemostasis of the prostate (MTG53)
Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate
-
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations about care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
-
COVID-19 rapid guideline: vitamin D (NG187)
This guideline covers vitamin D use in the context of COVID-19. It is for adults, young people and children in hospitals and community settings. Vitamin D is important for bone and muscle health. It may also have a role in the body's immune response to respiratory viruses.
-
Zio XT for detecting cardiac arrhythmias (MTG52)
Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias
-
COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 (NG186)
This guideline covers pharmacological VTE prophylaxis for patients being treated for COVID-19 pneumonia. It includes patients receiving treatment in hospital or in a community setting such as a ‘hospital at home’ service or COVID-19 ‘virtual ward’. The guideline applies to all patients with COVID-19 pneumonia, including those who have other conditions.
-
Volanesorsen for treating familial chylomicronaemia syndrome (HST13)
Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults
-
SEM Scanner 200 for preventing pressure ulcers (MTG51)
Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers
-
COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)
The purpose of this guideline is to provide recommendations for managing COVID-19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection.
-
COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NG173)
The purpose of this guideline is to ensure the best antibiotic management of suspected or confirmed bacterial pneumonia in adults in hospital during the COVID-19 pandemic. This includes people presenting to hospital with moderate to severe community-acquired pneumonia and people who develop pneumonia while in hospital. It will enable services to make the best use of NHS resources.
-
COVID-19 rapid guideline: cystic fibrosis (NG170)
The purpose of this guideline is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection.
-
COVID-19 rapid guideline: dialysis service delivery (NG160)
The purpose of this guideline is to maximise the safety of patients on dialysis, while protecting staff from infection. It will also enable dialysis services to make the best use of NHS resources and match the capacity of dialysis services to patient needs if these become limited because of the COVID-19 pandemic.
-
Axonics sacral neuromodulation system for treating refractory overactive bladder (MTG50)
Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder